中文版 | English
Title

Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer

Author
Corresponding AuthorHuang, Meijin; Huang, Jun
Publication Years
2023-03-01
DOI
Source Title
ISSN
1533-0028
EISSN
1938-0674
Volume22Issue:1
Abstract
The safety and efficacy of neoadjuvant PD-1 blockade immunotherapy for locally advanced dMMR/MSI-H CRC remain unclear. Eleven locally advanced dMMR/MSI-H CRC patients received 6 sintilimab (Innovent, LTD) injec-tions (200 mg/injection, every 3 weeks) before radical laparoscopic resection. 90.9% of the patients achieved pathological complete response (pCR). Single-agent neoadjuvant PD-1 antibody immunotherapy was safe and effective in locally advanced dMMR/MSI-H CRC. Background: PD-1 blockade has been recommended as first-line therapy for nonresectable or metastatic mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC). However, the safety and efficacy of neoadjuvant PD-1 blockade immunotherapy for locally advanced dMMR/MSI-H CRC remain unclear. Patients and Methods: From June 2020 to June 2022, 11 locally advanced dMMR/MSI-H CRC patients treated at the Sixth Affili-ated Hospital of Sun Yat-sen University (Guangzhou, China) were enrolled. All patients received 6 sintilimab (Innovent, LTD) injections (200 mg/injection, every 3 weeks) before radical laparoscopic resection. The patient clinical and patho-logical data were analyzed retrospectively. Results: dMMR was confirmed by immunohistochemistry for all patients. However, polymerase chain reaction (PCR) or next-generation sequencing confirmed MSI-H for only 90.9% (10/11) of the patients, while 1 patient had microsatellite stable (MSS) disease. After 6 injections of neoadjuvant anti-PD-1 therapy, 90.9% (10/11) of the patients (those confirmed to have dMMR and MSI-H disease) achieved pathological complete response (pCR). The other patient, who achieved major pathological response with residual tumor < 1%, had dMMR but MSS disease. No grade 3 or above immunotherapy-related adverse events occurred [Common Terminology Cr iter ia for Adverse Events ; version 5.0]. Overall, 72.7% (8/11) of the patients had grade 1-2 immunotherapy-related adverse events . No operational mortality or complications occurred within 30 days after surgery. Conclusion: Single -agent neoadjuvant PD-1 antibody immunotherapy was safe and effective in locally advanced dMMR/MSI-H CRC. Dual confirmation of MMR and MSI status by immunohistochemistry and next-generation sequencing or PCR is necessary for dMMR/MSI-H CRC patients before immunotherapy. The immunotherapy regimen used in this study deserves further validation in phase II and III clinical studies.
Keywords
URL[Source Record]
Indexed By
Language
English
SUSTech Authorship
Others
Funding Project
National Natural Science Foundation of C hina[81972885] ; 1010 project of the Sixth Affiliated Hospital of Sun Yat-sen University[1010CG (2020) -20]
WOS Research Area
Oncology
WOS Subject
Oncology
WOS Accession No
WOS:000957345000001
Publisher
Data Source
Web of Science
Citation statistics
Cited Times [WOS]:0
Document TypeJournal Article
Identifierhttp://kc.sustech.edu.cn/handle/2SGJ60CL/523942
DepartmentShenzhen People's Hospital
Affiliation
1.Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Yuan Cun Er Heng Rd 26, Guangzhou 510655, Peoples R China
2.Sun Yat Sen Univ, Affiliated Hosp 6, Dept Pathol, Guangzhou, Peoples R China
3.Jinan Univ, Southern Univ Sci & Technol, Shenzhen Peoples Hosp, Affiliated Hosp 1, Shenzhen, Guangdong, Peoples R China
4.Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Dis, Guangzhou, Peoples R China
5.Guangdong Inst Gastroenterol, Guangzhou, Peoples R China
Recommended Citation
GB/T 7714
Pei, Fengyun,Wu, Jingjing,Zhao, Yandong,et al. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer[J]. CLINICAL COLORECTAL CANCER,2023,22(1).
APA
Pei, Fengyun.,Wu, Jingjing.,Zhao, Yandong.,He, Wan.,Yao, Qijun.,...&Huang, Jun.(2023).Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.CLINICAL COLORECTAL CANCER,22(1).
MLA
Pei, Fengyun,et al."Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer".CLINICAL COLORECTAL CANCER 22.1(2023).
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Export to Excel
Export to Csv
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[Pei, Fengyun]'s Articles
[Wu, Jingjing]'s Articles
[Zhao, Yandong]'s Articles
Baidu Scholar
Similar articles in Baidu Scholar
[Pei, Fengyun]'s Articles
[Wu, Jingjing]'s Articles
[Zhao, Yandong]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Pei, Fengyun]'s Articles
[Wu, Jingjing]'s Articles
[Zhao, Yandong]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.